1. Profile
  2. Nathan Wray

Nathan Wray PhD

  • Medical Science Liaison (MSL), Collegium Pharmaceuticals
  • T32 in the Neuroscience of Mental Health Graduate
Profile Type
  • Alumni

Nathan Wray is a Medical Science Liaison (MSL) for Collegium Pharmaceuticals where he sets up collaborations with academic psychiatrists and pain specialists.

Nathan writes on his T32 experience:

For my thesis project in Mark Rasenick’s lab, I identified and characterized a novel NMDA receptor independent antidepressant action of ketamine. We hypothesized that ketamine would translocate Gas lipid rafts to non-raft microdomains, similarly to other antidepressants but with a distinct, abbreviated treatment duration. C6 glioma cells were treated with ketamine for 15 minutes (rather than 3 days as with other antidepressants), which translocated Gas-raft domains and increased the activation of adenylyl cyclase. These results reveal a novel antidepressant mechanism mediated by bfief ketamine treatment that may contribute to ketamine’s powerful antidepressant effect. Curiously, knocking out NMDA receptors had no effect on ketamine actions. They also suggest that the translocation of Gas lipid rafts is a reliable hallmark of antidepressant action that might be exploited for diagnosis or drug development. I now have three publications in top-tier journals I also have a textbook chapter and an invited review article in progress. The latter accepted and the former in prep, both of which will be published in 2020. In March 2018 I successfully defended my thesis and graduated in August 2018with a PhD in Neuroscience. Since graduation I have been working as a Medical Science Liaison (MSL) for Collegium Pharmaceutical. In this job, I have been setting up collaborations with academic psychiatrists and pain specialists. The translational aspects of the BNTP taught me the language necessary to do this job. Without the support of the T32 none of these accomplishments would have been possible.